Left ventricular hypertrophy, fibrosis heart, and diastolic dysfunction in chronic kidney disease

Area of Science:

• Cardiology
• Nephrology
• Pathophysiology

Context:

• Cardiovascular diseases (CVD) are the leading cause of death in chronic kidney disease (CKD) patients, accounting for 75-80% of morbidity and mortality.
• Key cardiovascular complications in CKD include sudden death, arrhythmias, heart failure, coronary artery disease, and myocardial infarction.
• Left ventricular hypertrophy (LVH) and cardiac fibrosis are primary drivers of heart failure and arrhythmias in the CKD population.

Purpose:

• To elucidate the pathophysiology of left ventricular hypertrophy (LVH) in CKD.
• To detail the mechanisms leading to cardiac fibrosis and its consequences.
• To understand the development of diastolic dysfunction in the context of CKD-related cardiac remodeling.

Summary:

• LVH in CKD is influenced by afterload, preload, and other factors, leading to cellular apoptosis and increased extracellular matrix production.
• This process results in cardiac fibrosis, impairing myocardial contractility, causing diastolic and systolic dysfunction, and potentially leading to dilated cardiomyopathy and congestive heart failure.
• The review categorizes pathophysiological factors contributing to LVH and outlines the progression from hypertrophy to fibrosis and subsequent cardiac dysfunction.

Impact:

• Provides a comprehensive understanding of the cardiac complications in CKD, crucial for developing targeted therapeutic strategies.
• Highlights the interconnectedness of kidney disease and heart health, emphasizing the need for integrated patient management.
• Aims to improve clinical outcomes for CKD patients by offering insights into the mechanisms underlying cardiovascular mortality.